MX2019010756A - Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). - Google Patents
Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).Info
- Publication number
- MX2019010756A MX2019010756A MX2019010756A MX2019010756A MX2019010756A MX 2019010756 A MX2019010756 A MX 2019010756A MX 2019010756 A MX2019010756 A MX 2019010756A MX 2019010756 A MX2019010756 A MX 2019010756A MX 2019010756 A MX2019010756 A MX 2019010756A
- Authority
- MX
- Mexico
- Prior art keywords
- quinoline derivatives
- novel imidazo
- disease
- lrrk2 inhibitors
- lrrk2
- Prior art date
Links
- ITIRVXDSMXFTPW-UHFFFAOYSA-N 1H-imidazo[4,5-c]quinoline Chemical class C1=CC=CC2=C(NC=N3)C3=CN=C21 ITIRVXDSMXFTPW-UHFFFAOYSA-N 0.000 title abstract 2
- 229940124786 LRRK2 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010024229 Leprosy Diseases 0.000 abstract 1
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 abstract 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469756P | 2017-03-10 | 2017-03-10 | |
| US201862629152P | 2018-02-12 | 2018-02-12 | |
| PCT/IB2018/051439 WO2018163066A1 (en) | 2017-03-10 | 2018-03-06 | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019010756A true MX2019010756A (es) | 2020-01-20 |
Family
ID=61683855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010756A MX2019010756A (es) | 2017-03-10 | 2018-03-06 | Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11312713B2 (https=) |
| EP (1) | EP3592741B1 (https=) |
| JP (1) | JP7219223B2 (https=) |
| KR (1) | KR102582626B1 (https=) |
| CN (1) | CN111051304B (https=) |
| AU (1) | AU2018230236B2 (https=) |
| BR (1) | BR112019018688A2 (https=) |
| CA (1) | CA3056030A1 (https=) |
| IL (1) | IL269214B (https=) |
| MX (1) | MX2019010756A (https=) |
| SG (2) | SG11201908322WA (https=) |
| TW (1) | TWI701246B (https=) |
| WO (1) | WO2018163066A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022022511A2 (pt) | 2020-05-06 | 2022-12-13 | Servier Lab | Inibidores macrocíclicos de lrrk2 quinase |
| EP4236950A4 (en) | 2020-10-29 | 2024-10-23 | Merck Sharp & Dohme LLC | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
| BR112023017834A2 (pt) | 2021-03-18 | 2023-10-03 | Servier Lab | Inibidores de lrrk2 cinase macrocíclicos |
| WO2023220238A1 (en) * | 2022-05-12 | 2023-11-16 | Interline Therapeutics, Inc. | Lrrk2 inhibitors |
| CN119403801A (zh) * | 2022-05-12 | 2025-02-07 | 因特来治疗公司 | Lrrk2抑制剂 |
| CN115728413A (zh) * | 2022-11-09 | 2023-03-03 | 内蒙古帕默康创医疗仪器有限公司 | 舍曲林血药浓度的定量分析方法 |
| CN116879450A (zh) * | 2023-07-25 | 2023-10-13 | 江苏汉邦科技股份有限公司 | 一种利用超临界流体色谱系统分离纯化芦可替尼前体的方法 |
| CN118440041B (zh) * | 2024-07-02 | 2024-09-27 | 苏州凯瑞医药科技有限公司 | 一种手性4-氨基-3-羟基四氢吡喃的制备方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| CA1335996C (en) * | 1988-02-16 | 1995-06-20 | Susumu Takada | 2-substituted carbonylimidazo¬4,5-c|quinolines |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| ATE239797T1 (de) | 1993-01-25 | 2003-05-15 | Takeda Chemical Industries Ltd | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| NZ337765A (en) | 1997-04-09 | 2001-09-28 | Mindset Biopharmaceuticals Usa | Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease |
| ES2287971T3 (es) | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| CA2427661C (en) | 2000-11-03 | 2013-05-28 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| US20040146512A1 (en) | 2002-10-09 | 2004-07-29 | Arnon Rosenthal | Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| BRPI0410630A (pt) | 2003-06-19 | 2006-06-13 | Pfizer Prod Inc | antagonista de nk1 |
| MY157827A (en) | 2003-06-27 | 2016-07-29 | 3M Innovative Properties Co | Sulfonamide substituted imidazoquinolines |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| AR046845A1 (es) | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| EP1720847A1 (en) | 2004-02-02 | 2006-11-15 | Pfizer Products Incorporated | Histamine-3 receptor modulators |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| US20090074775A1 (en) | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| DE602006018301D1 (de) | 2005-06-22 | 2010-12-30 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| CA2624625A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| CA2643055A1 (en) | 2006-03-13 | 2007-09-20 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| JP4585610B2 (ja) | 2007-01-22 | 2010-11-24 | ファイザー・プロダクツ・インク | 治療用化合物のトシル酸塩およびその医薬組成物 |
| ITMI20070890A1 (it) | 2007-05-04 | 2008-11-05 | Sifi Spa | Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma |
| GB201008134D0 (en) | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| WO2011144622A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | 1h - imidazo [4, 5 - c] quinolines |
| WO2012028629A1 (en) | 2010-09-02 | 2012-03-08 | Glaxo Group Limited | 2 - (benzyloxy) benzamides as lrrk2 kinase inhibitors |
| US9233977B2 (en) | 2010-10-29 | 2016-01-12 | Merck Sharp & Dohme Corp. | Leucine-rich repeat kinase enzyme activity |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| US20150218172A1 (en) | 2012-10-04 | 2015-08-06 | Pfizer Limited | Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors |
| WO2014060113A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Novel kinase inhibitors |
| ITTO20130694A1 (it) * | 2013-08-14 | 2015-02-15 | Umbra Meccanotecnica | Giunto washpipe per un impianto di perforazione petrolifera |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
| WO2016108130A1 (en) | 2014-12-30 | 2016-07-07 | Sun Pharmaceutical Industries Limited | Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds |
| RU2722149C1 (ru) * | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| EP3463344A4 (en) | 2016-06-01 | 2020-02-12 | Harold Richard Hellstrom | TREATMENT OF DRY EYE WITH PARASYMPATHIC AND ANTISYMPATHIC AGENTS |
| WO2018163030A1 (en) * | 2017-03-10 | 2018-09-13 | Pfizer Inc. | Cyclic substituted imidazo[4,5-c]quinoline derivatives |
-
2018
- 2018-03-06 AU AU2018230236A patent/AU2018230236B2/en active Active
- 2018-03-06 CA CA3056030A patent/CA3056030A1/en active Pending
- 2018-03-06 US US16/492,558 patent/US11312713B2/en active Active
- 2018-03-06 WO PCT/IB2018/051439 patent/WO2018163066A1/en not_active Ceased
- 2018-03-06 KR KR1020197029735A patent/KR102582626B1/ko active Active
- 2018-03-06 CN CN201880029989.5A patent/CN111051304B/zh active Active
- 2018-03-06 EP EP18711703.1A patent/EP3592741B1/en active Active
- 2018-03-06 SG SG11201908322W patent/SG11201908322WA/en unknown
- 2018-03-06 MX MX2019010756A patent/MX2019010756A/es unknown
- 2018-03-06 JP JP2019549462A patent/JP7219223B2/ja active Active
- 2018-03-06 BR BR112019018688A patent/BR112019018688A2/pt not_active Application Discontinuation
- 2018-03-06 SG SG10202110112T patent/SG10202110112TA/en unknown
- 2018-03-07 TW TW107107734A patent/TWI701246B/zh active
-
2019
- 2019-09-09 IL IL269214A patent/IL269214B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020510046A (ja) | 2020-04-02 |
| AU2018230236A1 (en) | 2019-10-31 |
| JP7219223B2 (ja) | 2023-02-07 |
| CN111051304A (zh) | 2020-04-21 |
| EP3592741B1 (en) | 2023-02-15 |
| SG11201908322WA (en) | 2019-10-30 |
| US20210355117A1 (en) | 2021-11-18 |
| BR112019018688A2 (pt) | 2020-04-07 |
| NZ757971A (en) | 2024-12-20 |
| WO2018163066A1 (en) | 2018-09-13 |
| RU2019131727A3 (https=) | 2021-04-26 |
| US11312713B2 (en) | 2022-04-26 |
| TWI701246B (zh) | 2020-08-11 |
| TW201900642A (zh) | 2019-01-01 |
| IL269214B (en) | 2022-03-01 |
| EP3592741A1 (en) | 2020-01-15 |
| AU2018230236B2 (en) | 2022-05-19 |
| SG10202110112TA (en) | 2021-10-28 |
| RU2019131727A (ru) | 2021-04-12 |
| IL269214A (en) | 2019-11-28 |
| CA3056030A1 (en) | 2018-09-13 |
| CN111051304B (zh) | 2022-12-27 |
| KR102582626B1 (ko) | 2023-09-22 |
| KR20190138793A (ko) | 2019-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX377305B (es) | DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2. | |
| MX2019010756A (es) | Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). | |
| PH12014502886A1 (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| MY210086A (en) | Pharmaceutical compounds | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| TW201613593A (en) | Molecules for administration to ROS1 mutant cancer cells | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| PH12016502168A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| BR112013001088A2 (pt) | "derivados substituídos como inibidores a quinase de imidazoquinolina" | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| TN2015000005A1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| WO2014106800A8 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
| EA201992090A1 (ru) | ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| MX379704B (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida | |
| CU20140140A7 (es) | 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 | |
| TH101974B (th) | วิธีการสำหรับการเตรียมเบนซีน ซึ่งถูกแทนที่ด้วยไตรคลอโรเมธิล |